The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuroendocrine Carcinoma Treatment Market Research Report 2025
Synopsis
The global Neuroendocrine Carcinoma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma Treatment.
Report Scope
The Neuroendocrine Carcinoma Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuroendocrine Carcinoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuroendocrine Carcinoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Chiasma, Inc.
Ipsen
AbbVie
Bausch Health
Jubilant
Teva Pharmaceutical Industries Ltd.
Roche
Mateon
Segment by Type
Somatostatin Analogs
Targeted Therapy
Chemotherapy
Segment by Application
Hospitals
Clinics
Oncology Centers
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Carcinoma Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Neuroendocrine Carcinoma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma Treatment.
Report Scope
The Neuroendocrine Carcinoma Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuroendocrine Carcinoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuroendocrine Carcinoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Chiasma, Inc.
Ipsen
AbbVie
Bausch Health
Jubilant
Teva Pharmaceutical Industries Ltd.
Roche
Mateon
Segment by Type
Somatostatin Analogs
Targeted Therapy
Chemotherapy
Segment by Application
Hospitals
Clinics
Oncology Centers
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Carcinoma Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Somatostatin Analogs
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.3 Market by Application
1.3.1 Global Neuroendocrine Carcinoma Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Oncology Centers
1.3.5 Ambulatory Surgical Centers
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Treatment Market Perspective (2019-2030)
2.2 Neuroendocrine Carcinoma Treatment Growth Trends by Region
2.2.1 Global Neuroendocrine Carcinoma Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuroendocrine Carcinoma Treatment Historic Market Size by Region (2019-2024)
2.2.3 Neuroendocrine Carcinoma Treatment Forecasted Market Size by Region (2025-2030)
2.3 Neuroendocrine Carcinoma Treatment Market Dynamics
2.3.1 Neuroendocrine Carcinoma Treatment Industry Trends
2.3.2 Neuroendocrine Carcinoma Treatment Market Drivers
2.3.3 Neuroendocrine Carcinoma Treatment Market Challenges
2.3.4 Neuroendocrine Carcinoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue
3.1.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue (2019-2024)
3.1.2 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Neuroendocrine Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Treatment Revenue
3.4 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio
3.4.1 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Treatment Revenue in 2023
3.5 Neuroendocrine Carcinoma Treatment Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service
3.7 Date of Enter into Neuroendocrine Carcinoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuroendocrine Carcinoma Treatment Breakdown Data by Type
4.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Type (2019-2024)
4.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2025-2030)
5 Neuroendocrine Carcinoma Treatment Breakdown Data by Application
5.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Application (2019-2024)
5.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuroendocrine Carcinoma Treatment Market Size (2019-2030)
6.2 North America Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024)
6.4 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuroendocrine Carcinoma Treatment Market Size (2019-2030)
7.2 Europe Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024)
7.4 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size (2019-2030)
8.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Treatment Market Size (2019-2030)
9.2 Latin America Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024)
9.4 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size (2019-2030)
10.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Treatment Introduction
11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Neuroendocrine Carcinoma Treatment Introduction
11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Chiasma, Inc.
11.3.1 Chiasma, Inc. Company Detail
11.3.2 Chiasma, Inc. Business Overview
11.3.3 Chiasma, Inc. Neuroendocrine Carcinoma Treatment Introduction
11.3.4 Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.3.5 Chiasma, Inc. Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Detail
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Neuroendocrine Carcinoma Treatment Introduction
11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.4.5 Ipsen Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Detail
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Neuroendocrine Carcinoma Treatment Introduction
11.5.4 AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.5.5 AbbVie Recent Development
11.6 Bausch Health
11.6.1 Bausch Health Company Detail
11.6.2 Bausch Health Business Overview
11.6.3 Bausch Health Neuroendocrine Carcinoma Treatment Introduction
11.6.4 Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.6.5 Bausch Health Recent Development
11.7 Jubilant
11.7.1 Jubilant Company Detail
11.7.2 Jubilant Business Overview
11.7.3 Jubilant Neuroendocrine Carcinoma Treatment Introduction
11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.7.5 Jubilant Recent Development
11.8 Teva Pharmaceutical Industries Ltd.
11.8.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.8.3 Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Introduction
11.8.4 Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.8.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Neuroendocrine Carcinoma Treatment Introduction
11.9.4 Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.9.5 Roche Recent Development
11.10 Mateon
11.10.1 Mateon Company Detail
11.10.2 Mateon Business Overview
11.10.3 Mateon Neuroendocrine Carcinoma Treatment Introduction
11.10.4 Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024)
11.10.5 Mateon Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Somatostatin Analogs
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Global Neuroendocrine Carcinoma Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Neuroendocrine Carcinoma Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Neuroendocrine Carcinoma Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Neuroendocrine Carcinoma Treatment Market Share by Region (2019-2024)
Table 9. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Neuroendocrine Carcinoma Treatment Market Share by Region (2025-2030)
Table 11. Neuroendocrine Carcinoma Treatment Market Trends
Table 12. Neuroendocrine Carcinoma Treatment Market Drivers
Table 13. Neuroendocrine Carcinoma Treatment Market Challenges
Table 14. Neuroendocrine Carcinoma Treatment Market Restraints
Table 15. Global Neuroendocrine Carcinoma Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Neuroendocrine Carcinoma Treatment Market Share by Players (2019-2024)
Table 17. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2023)
Table 18. Ranking of Global Top Neuroendocrine Carcinoma Treatment Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service
Table 22. Date of Enter into Neuroendocrine Carcinoma Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuroendocrine Carcinoma Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Neuroendocrine Carcinoma Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2019-2024)
Table 30. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2025-2030)
Table 32. North America Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Neuroendocrine Carcinoma Treatment Product
Table 50. Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Novartis Company Detail
Table 53. Novartis Business Overview
Table 54. Novartis Neuroendocrine Carcinoma Treatment Product
Table 55. Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Chiasma, Inc. Company Detail
Table 58. Chiasma, Inc. Business Overview
Table 59. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Product
Table 60. Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 61. Chiasma, Inc. Recent Development
Table 62. Ipsen Company Detail
Table 63. Ipsen Business Overview
Table 64. Ipsen Neuroendocrine Carcinoma Treatment Product
Table 65. Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 66. Ipsen Recent Development
Table 67. AbbVie Company Detail
Table 68. AbbVie Business Overview
Table 69. AbbVie Neuroendocrine Carcinoma Treatment Product
Table 70. AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 71. AbbVie Recent Development
Table 72. Bausch Health Company Detail
Table 73. Bausch Health Business Overview
Table 74. Bausch Health Neuroendocrine Carcinoma Treatment Product
Table 75. Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 76. Bausch Health Recent Development
Table 77. Jubilant Company Detail
Table 78. Jubilant Business Overview
Table 79. Jubilant Neuroendocrine Carcinoma Treatment Product
Table 80. Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 81. Jubilant Recent Development
Table 82. Teva Pharmaceutical Industries Ltd. Company Detail
Table 83. Teva Pharmaceutical Industries Ltd. Business Overview
Table 84. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Product
Table 85. Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 86. Teva Pharmaceutical Industries Ltd. Recent Development
Table 87. Roche Company Detail
Table 88. Roche Business Overview
Table 89. Roche Neuroendocrine Carcinoma Treatment Product
Table 90. Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 91. Roche Recent Development
Table 92. Mateon Company Detail
Table 93. Mateon Business Overview
Table 94. Mateon Neuroendocrine Carcinoma Treatment Product
Table 95. Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2019-2024) & (US$ Million)
Table 96. Mateon Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Carcinoma Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Neuroendocrine Carcinoma Treatment Market Share by Type: 2023 VS 2030
Figure 3. Somatostatin Analogs Features
Figure 4. Targeted Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Global Neuroendocrine Carcinoma Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Oncology Centers Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Neuroendocrine Carcinoma Treatment Report Years Considered
Figure 14. Global Neuroendocrine Carcinoma Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Neuroendocrine Carcinoma Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Neuroendocrine Carcinoma Treatment Market Share by Region: 2023 VS 2030
Figure 17. Global Neuroendocrine Carcinoma Treatment Market Share by Players in 2023
Figure 18. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Treatment Revenue in 2023
Figure 20. North America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Neuroendocrine Carcinoma Treatment Market Share by Country (2019-2030)
Figure 22. United States Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Neuroendocrine Carcinoma Treatment Market Share by Country (2019-2030)
Figure 26. Germany Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Region (2019-2030)
Figure 34. China Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Neuroendocrine Carcinoma Treatment Market Share by Country (2019-2030)
Figure 42. Mexico Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Country (2019-2030)
Figure 46. Turkey Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 50. Chiasma, Inc. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 51. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 52. AbbVie Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 53. Bausch Health Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 54. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 55. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 56. Roche Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 57. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
